Velcade - Bortezomib for injection - MILLENNIUM - Proteasome Inhibitor approved for treatment of relapsed mantle cell lymphoma

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2007年 / 42卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [31] Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
    Zinzani, Pier Luigi
    Musuraca, Gerardo
    Tani, Monica
    Stefoni, Vittorio
    Marchi, Enrica
    Fina, Mariapaola
    Pellegrini, Cinzia
    Alinari, Lapo
    Derenzini, Enrico
    de Vivo, Antonio
    Sabattini, Elena
    Pileri, Stefano
    Baccarani, Michele
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) : 4293 - 4297
  • [32] Phase II trial of the proteasome inhibitor bortezomib (PS-341, Velcade™) in patients with relapsed/refractory multiple myeloma
    不详
    [J]. CLINICAL LYMPHOMA, 2003, 4 (01): : 11 - 12
  • [33] Altered cellular protein levels of tumor suppressor genes and heat shock elements (TRAP1) indicate sensitivity to the proteasome inhibitor bortezomib (Velcade®) in mantle cell lymphoma.
    Weinkauf, M
    Rieken, M
    Pastore, A
    Hartmann, E
    Rosenwald, A
    Hiddemann, W
    Dreyling, MH
    [J]. BLOOD, 2005, 106 (11) : 681A - 682A
  • [34] Bortezomib treatment for patients with mantle-cell lymphoma
    Tanday, Sanjay
    [J]. LANCET ONCOLOGY, 2015, 16 (04): : E162 - E162
  • [35] Proteasome inhibitor bortezomib (Velcade™) and trastuzumab in HER-2 overexpressing breast cancer cell lines
    Laes, JF
    Cardoso, F
    Durbecq, V
    Lagneaux, L
    Hennuy, B
    Lallemand, F
    Gonze, I
    Di Leo, A
    Kern, F
    Ross, J
    Piccart, MJ
    Sotiriou, C
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S89 - S89
  • [36] Metabolism of the peptide boronic acid proteasome inhibitor bortezomib (VELCADE™) in multiple species
    LaButti, J
    Pekol, T
    Wang, RH
    Hsieh, F
    Daniels, JS
    Nix, D
    Gan, LS
    Miwa, G
    [J]. DRUG METABOLISM REVIEWS, 2003, 35 : 41 - 41
  • [37] Bortezomib in mantle cell lymphoma
    Sub, K. Stephen
    Goy, Andre
    [J]. FUTURE ONCOLOGY, 2008, 4 (02) : 149 - 168
  • [38] Fludarabine, Bortezomib, Myocet® and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma
    Orciuolo, Enrico
    Buda, Gabriele
    Pelosini, Matteo
    Petrini, Mario
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (05) : 810 - 812
  • [39] The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer
    Thaler, Sonja
    Thiede, Gitta
    Hengstler, Jan G.
    Schad, Arno
    Schmidt, Marcus
    Sleeman, Jonathan P.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (03) : 686 - 697
  • [40] 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma
    Weinkauf, Marc
    Zimmermann, Yvonne
    Hartmann, Elena
    Rosenwald, Andreas
    Rieken, Malte
    Pastore, Alessandro
    Hutter, Grit
    Hiddemann, Wolfgang
    Dreyling, Martin
    [J]. ELECTROPHORESIS, 2009, 30 (06) : 974 - 986
12345